Status: Recruiting
CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
CD70 is a promising target for immunotherapy because it is overexpressed in T-cell lymphoma (TCL) and acute myeloid leukemia (AML) tumor cells but is found in deficient levels in normal tissues and hematopoietic stem cells. This study aims to evaluate the safety and efficacy of CD70-targeted CAR-NK (CD70-CAR-NK) cells in patients with relapsed and refractory TCL and AML.
Participants needed: 25
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Second Affiliated Hospital, School of Medicine, Zhejiang UniversityUpdated: Apr 30, 2026Locations: 1
Eligibility criteria
Voluntarily participate in this study and sign the informed consent form; [+18]
Those with a history of allergy to any component in the cellular product; [+11]